---
title: "HC Wainwright & Co. maintains Buy rating on Tyra Biosciences, $29 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299749074.md"
description: "HC Wainwright & Co. maintains a Buy rating on Tyra Biosciences with a $29 price target, implying 13.1% upside from the September 21 close. The firm highlights Tyra's promising pipeline of three clinical-stage FGFR-targeting small molecules and its proprietary SNAP platform for precise drug design, citing these factors as drivers for future growth in oncology and enhanced investor confidence."
datetime: "2026-09-22T10:19:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299749074.md)
  - [en](https://longbridge.com/en/news/299749074.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299749074.md)
generator: "portal-rs"
---

# HC Wainwright & Co. maintains Buy rating on Tyra Biosciences, $29 price target

HC Wainwright & Co. maintained their Buy rating on Tyra Biosciences's stock with a price target of $29.00.

The price target implies an upside of 13.1% from the Sep 21 close of $25.65.

**Key takeaways from the analyst note**

**Strong Pipeline of Novel Drug Candidates**: Tyra Biosciences has a promising pipeline with three clinical-stage small molecules targeting FGFR, designed to address the limitations of existing treatments, which positions the company well for future growth in the oncology market.

**Innovative Precision Medicine Platform**: The company's proprietary SNAP platform allows for rapid and precise drug design, increasing the likelihood of developing highly effective therapies that could lead to better patient outcomes, thereby enhancing investor confidence.

Explore more price target data and ratings for Tyra Biosciences on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TYRA.US](https://longbridge.com/en/quote/TYRA.US.md)

## Related News & Research

- [Oppenheimer reiterates Outperform rating on Tyra Biosciences, $40 price target](https://longbridge.com/en/news/299797255.md)
- [Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45](https://longbridge.com/en/news/298055291.md)
- [Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead](https://longbridge.com/en/news/298782816.md)
- [CoreWeave Bond Yields Hit 15.5%, Shares Sink to 17-Month Lows](https://longbridge.com/en/news/302440124.md)
- [SEA (NYSE:SE) Stock Sees Unusually High Call Option Buying](https://longbridge.com/en/news/302449321.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**